Fontolizumab (planned trade name HuZAF) is a humanized monoclonal antibody and an immunosuppressive drug for the treatment of auto-immune diseases like Crohn's disease.
Fontolizumab (planned trade name HuZAF) is a humanized monoclonal antibody and an immunosuppressive agent for the treatment of autoimmune disorders such as Crohn's disease.